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Abstract
Cell proliferation, migration, and capillary network
formation of endothelial cells are the fundamental
steps for angiogenesis, which involves the formation
of new blood vessels. The purpose of this study is
to investigate the effect of a novel aminothiazole SNS-
032 on these critical steps for in vitro angiogenesis
using a coculture system consisting of human um-
bilical vein endothelial cells (HUVECs) and human
glioblastoma cells (U87MG). SNS-032 is a potent se-
lective inhibitor of cyclin-dependent kinases 2, 7, and
9, and inhibits both transcription and cell cycle. In this
study, we examined the proliferation and viability of
HUVECs and U87MG cells in the presence of SNS-032
and observed a dose-dependent inhibition of cellular
proliferation in both cell lines. SNS-032 inhibited three-
dimensional capillary network formations of endothe-
lial cells. In a coculture study, SNS-032 completely
prevented U87MG cell–mediated capillary formation of
HUVECs. This inhibitor also prevented the migration of
HUVECs when cultured alone or cocultured with
U87MG cells. In addition, SNS-032 significantly pre-
vented the production of vascular endothelial growth
factor (VEGF) in both cell lines, whereas SNS-032 was
less effective in preventing capillary network formation
and migration of endothelial cells when an active
recombinant VEGF was added to the medium. In
conclusion, SNS-032 prevents in vitro angiogenesis,
and this action is attributable to blocking of VEGF.
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Introduction
Angiogenesis is a physiological process intrinsic to the
formation of new blood vessels from the preexisting vas-
culature. This complex process is also integral to the
development and progression of tumors, which involve
endothelial cell migration, proliferation, and differentiation,
as well as tube formation [1,2]. Angiogenesis is stimulated
by several growth factors, including basic fibroblast growth
factor (FGF), platelet-derived growth factor (PDGF), transform-
ing growth factor-a, and vascular endothelial growth factor
(VEGF) family [1,3–6]. Among these, VEGF is the most potent
tumor angiogenic factor, which acts on endothelial cells and
plays a central role in their proliferation, migration, and sur-
vival. VEGF is expressed abundantly by most human and
animal tumors [7,8]. One of the most highly angiogenic primary
solid tumors is human glioblastoma, which secretes a large
quantity of VEGF [9,10]. Human glioblastoma U87MG cells
express three major VEGF isoforms: VEGF121, VEGF165, and
VEGF185, all of which are essential for the formation of new
blood vessels and for aggressive growth of tumors [11,12].
Tumor growth and metastasis are angiogenesis-dependent.
Blocking angiogenesis, specifically targeting VEGF and its
receptors, is, therefore, a feasible strategy for preventing tumor
growth and metastasis [13–17]. Several strategies have been
used to target VEGF and its receptors, such as: 1) monoclonal
antibodies that compete with activating ligands for binding with
extracellular domain; and 2) small molecules that inhibit intra-
cellular tyrosine kinase activity. An anti-VEGF monoclonal
antibody, bevacizumab (Avastin; Genentech, Oceanside,
CA), has now been approved as first-line therapy in the
treatment of metastatic colon carcinoma, in combination with
standard chemotherapy [18]. However, the role of anti-VEGF
therapy in the treatment of other solid tumors is currently under
intense investigation.
Perturbation of cell cycle regulation is a key factor in most
human neoplasias [19]. The regulatory proteins that play key
roles in controlling cell cycle progression are cyclins, cyclin-
dependent kinases (CDKs), their substrate proteins, CDK in-
hibitors, and the tumor-suppressor gene products p53 and
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pRb. Several CDK inhibitors, such as flavopiridol, UCN-01,
CYC202, and SNS-032 (formerly known as BMS-387032),
are undergoing clinical evaluation [20,21]. Flavopiridol, a
pan-CDK inhibitor, is effective as an anticancer agent that is
associated with arresting cell growth, inducing apoptosis,
inhibiting cell migration, and preventing angiogenesis [22].
In earlier reports, Brusselbach et al. [23] demonstrated the
induction of apoptosis in human umbilical vein endothelial
cells (HUVECs) by flavopitridol and possibly through the
downregulation of survivin. Hypoxic conditions in the tumor
microenvironment have been shown to induce elevated
VEGF levels. It has been also reported that flavopiridol
prevents hypoxia-induced VEGF in several cellular systems,
including human gliomas and monocytes [24,25].
The major purposes of this research are to use a more
selective CDK inhibitor and to demonstrate its efficacy in the
prevention of tumor angiogenesis. A newer generation of
CDK antagonists (such as SNS-032) that are more selective
and less cytotoxic is now entering into clinical trials [26].
However, it is not known whether this improved selectivity
retains antitumor and antiangiogenic property or compro-
mises it. Therefore, it is necessary to obtain a clear under-
standing of whether selective inhibition of a small cohort of
CDKs impacts angiogenesis. Preclinical studies have shown
that SNS-032 induces cell cycle arrest and apoptosis across
multiple cell lines. In our recent report, we demonstrated that
SNS-032 strongly inhibits cyclooxygenase-2 (COX-2) ex-
pression induced by the proinflammatory cytokine IL-1b
[27]. COX-2 has been widely proven to play a crucial role
in tumor angiogenic development and cancer metastasis
[28–30]. COX-2 inhibitors may also inhibit tumor angio-
genesis, reducing prostaglandin (PG) production by acting
on several potential cell sources such as tumor cells, endo-
thelial cells, and stromal reactive cells [31–33]. The possible
induction of VEGF expression by PGE1 and PGE2 in a non-
neoplastic cell system suggests the probable role of COX-2
in the expression of VEGF and the regulation of tumor
angiogenesis [34,35].
To the best of our knowledge, this is the first report to
suggest that SNS-032 prevents tumor cell– induced VEGF
secretion and in vitro angiogenesis in a tumor coculture
model. As an initial step, we determined the effect of this
inhibitor on endothelial cell proliferation, migration, and cap-
illary formation. We then investigated these critical steps
of angiogenesis in endothelial cells when cocultured with
glioma cells in the presence of SNS-032. In addition, we
demonstrated that SNS-032 significantly prevented the pro-
duction of VEGF in both cell lines.
Materials and Methods
Cell Culture
The human glioblastoma U87MG cell line was purchased
from the American Type Culture Collection (Manassas, VA).
The cell line was maintained in Dulbecco’s modified Eagle’s
medium (DMEM; Gibco-BRL, Buffalo/Grand Island, NY)
supplemented with 10% fetal bovine serum, 50 U/ml penicil-
lin, 50 mg/ml streptomycin, 2 mM L-glutamine, and 25 mM
HEPES. For all experiments, cells were grown to 75%
confluency and then treated as indicated. HUVECs were
purchased from Cell Applications, Inc. (San Diego, CA), and
maintained in an endothelial cell growth medium (Cell Appli-
cations, Inc.). Both U87MG and HUVECs were cultured in a
humidified atmosphere containing 5% CO2 at 37jC.
Materials
CDK inhibitor SNS-032 (MW = 416.99) was obtained from
Sunesis Pharmaceuticals, Inc. (San Francisco, CA), dissolved
in distilled water as a 10-mM stock solution, and stored at
20jC in 100-ml aliquots. Penicillin, streptomycin, fetal bo-
vine serum, and L-glutamine were obtained from Invitrogen
(Grand Island, NY). Recombinant human VEGF was pur-
chased from R&D Systems (Minneapolis, MN). VEGF ELISA
Development Kit was purchased from Peprotech, Inc. (Rocky
Hill, NJ). Antiactin antibody was purchased from Sigma
Aldrich Co. (St. Louis, MO). Both standard Matrigel matrix
membrane and growth factor– reduced Matrigel matrix
membrane were purchased from BD Biosciences Discovery
Labware (Bedford, MA).
Cell Viability Assay and Growth Analysis
Cell Titer-Glo (CTG; Promega, Madison, WI) luminescent
assay was performed to measure the growth curves of both
HUVECs and U87MG cells. This luminescent assay de-
termines the presence of live cells in a growing culture
based on the quantitation of adenosine triphosphate re-
leased by metabolically active cells. Briefly, U87MG cells
and HUVECs (2000 cells/well) were seeded in a 96-well
microplate (Falcon, Franklin Lakes, NJ) in a final volume
of 100 ml. After 24 hours, cells were treated with various
doses of SNS-032 (0–0.5 mM) for 24, 48, or 72 hours. After
completion of the treatment, 100 ml of CTG solution was
added to each well and incubated for 20 minutes at room
temperature in the dark. Lysate (50 ml) was transferred to a
96-well white plate (GREINER 216002, Frickenhausen, Ger-
many), and luminescence was measured by POLARstar
OPTIMA, a microplate-based multidetection reader from
BMG LABTECH (Offenburg, Germany). Each point repre-
sents the mean ± SD (bars) of four values from two inde-
pendent experiments. Percent cell growth was calculated
by considering 100% growth at the time of SNS-032 addition.
Trypan blue exclusion (TBE) assay was performed to
measure cell viability. Briefly, HUVECs and U87MG cells
(3  105) were seeded in a 60-mm dish. Experimental con-
ditions were the same as mentioned in the CTG assay. After
treatment for indicated times, cells were trypsinized, and
monolayer cell suspensions were prepared by the collec-
tion of both attached and floating cells. Resuspended cells
and 0.4% trypan blue (Sigma-Aldrich Co.) solutions were
mixed in equal volume, incubated at room temperature for
10 minutes, and then counted using a standard hemo-
cytometer (Fisher Scientific, Itasca, IL). Viable cells (un-
stained) and nonviable cells (stained blue) were counted,
and percent cell viability was calculated as: total viable cells
(unstained)/total cells (stained + unstained) 100.
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Tube Formation Assay
We used standard Matrigel assay to evaluate in vitro
angiogenesis activity by quantifying the tube formation of
HUVECs, as previously described [36–38]. Briefly, 48-well
culture plates were coated with 200 ml of Matrigel per well
then allowed to polymerize for 30 minutes at 37jC. SNS-032
at indicated concentrations was added to HUVEC suspen-
sion 30 minutes before seeding. Cell suspensions of 150 ml
(1.5  104 cells) were seeded on polymerized Matrigel.
After incubation at 37jC for 8 hours, each culture was
photographed at 100 magnification using a Nikon (Melville,
NY) camera connected to an inverted microscope. There are
three parameters by which capillary structure formation can
be measured: capillary length, number of capillaries or
branched tubes, and relative capillary area per field. Tube
formation was quantified from four randomly selected fields
per experiment by measuring the total additive length of all
cellular structures, including all branches, using a scale ruler.
To examine the effect of SNS-032 on tumor cell– induced
tube formation of HUVECs, a conditioned medium was
collected from U87MG cells as indicated and used as the
growth medium for HUVECs. Briefly, cells were seeded
at 70% confluency; after overnight incubation, cells were
treated in the presence or in the absence of SNS-032, as
indicated, for 8 hours. After 8 hours, cells were washed
thoroughly with 1 phosphate-buffered saline (PBS) and
further incubated in reduced serum containing DMEM for
another 24 hours and collected as a conditioned medium.
The conditioned medium was then used to study the in vitro
tube formation assay in HUVECs, as described above.
To examine the effect of SNS-032 on VEGF-induced tube
formation, HUVECs suspended in endothelial cell basal
medium containing 0.5% fetal bovine serum (FBS) were
seeded on a culture plate coated with growth factor–reduced
Matrigel. SNS-032 (0.5 mM) was added to the cell suspen-
sion 30 minutes before plating the cells, and recombinant
human VEGF165 (100 ng/ml) was added at the time of
seeding as indicated.
Cell Migration Assay
To investigate the cell migration of HUVECs, 8-mm-pore-
size polyethylene tetraphthalate (PET) membrane inserts for
24-well plates were used (Becton Dickinson, Bedford, MA).
HUVECs (2  104) in 500 ml of medium with or without SNS-
032 were seeded onto the upper compartment (insert) of
each chamber and placed into wells containing 750 ml of
complete medium. Migration chambers were then incubated
for 8 hours in 5% CO2 and 95% humidified air atmosphere
at 37jC to allow cells to migrate through the membrane.
Following incubation, the inserts were fixed in absolute
methanol for 2 minutes at room temperature and stained
with 1% toluidine blue in 1% borax for 3 minutes. The cells on
the upper surface of the insert were removed with a cotton-
tipped swab. Images were taken using a Nikon camera
connected to an inverted microscope (final magnification,
200). Quantitation of migrating cells on the lower surface of
each filter was done by manually counting 10 random fields.
Each assay was performed in duplicate and repeated thrice.
The data collected from independent experiments were
pooled for statistical analysis.
To assay for glioblastoma cell– induced migration of endo-
thelial cells, we performed a coculture assay using migration
chambers as described by Tsujii et al. [29]. Briefly, U87MG
cells were plated (70% confluency) in the outer chamber of a
24-well plate. After overnight incubation, the cells were
treated with or without SNS-032, as indicated, for 8 hours.
After this incubation period, the cells were thoroughly washed
using 1 PBS and further incubated in reduced serum (2%)
containing DMEM for another 24 hours. An insert containing
20,000 endothelial cells was then placed onto the outer
chamber. After 12 hours of incubation at 37jC, migrated cells
were analyzed using the same procedure as described above.
Tomeasure VEGF-inducedmigration, HUVECswere sus-
pended in growth factor–reduced endothelial cell medium
and seeded in the insert with or without SNS-032. Re-
combinant VEGF (100 ng/ml) was then added to both inner
and outer chambers containing growth factor–reduced me-
dium. After 12 hours of incubation at 37jC, migrated cells
were analyzed.
VEGF Quantification By Enzyme-Linked Immunosorbent
Assay (ELISA)
The VEGF protein that was released into the conditioned
medium of U87MG cells was measured using a commer-
cially available human VEGF ELISA Development Kit
(Peprotech, Inc.). Cells (5  105) were seeded in six-well
plates in 2 ml of complete growth medium. Twenty-four hours
later, cells were serum-starved for 24 hours and then ex-
posed to SNS-032 (0–0.5 mM) with 1 ml of DMEM con-
taining 2% FBS. After 24 hours of incubation in 5% CO2 at
37jC and 95% humidified air to allow VEGF protein se-
cretion, the conditioned medium was collected, and 1 mM
phenyl methyl sulphonyl fluoride (PMSF) was added. The
supernatant was clarified by centrifugation for 5 minutes at
14,000 rpm, aliquoted, and stored at 80jC until analysis.
Isolation and Analysis of RNA
U87MG cells were treated as indicated. Total RNA was
isolated using TRIzol (Invitrogen, Carlsbad, CA) according to
the manufacturer’s protocol, quantified by measuring absor-
bance at 260 nm, and stored at70jC. Single-tube one-step
reverse transcription–polymerase chain reaction (RT-PCR)
was performed using a one-step RT-PCR kit (Invitrogen). The
assay was carried out in a 50-ml reaction mixture containing
2 ml (100 ng) of total RNA, 200 nM of VEGF primers 5V-
CGAAGTGGTGAAGTTCATGGATG-3V (sense) and 5V-
TTCTGTATCAGTCTTTCCTGGT-3V (antisense), 100 nM of
b-actin primers 5V-GTACCACTGGCATCGTGATGGACT-3V
(sense) and 5V-ATCCACACGGAGTACTTGCGCTCA-3V
(antisense), 25 ml of a 2 reaction mixture (0.4 mM of each
dNTP, 3.2 mM MgSO4), and 2 ml of a SuperScript III/RT
Platinum Taq Mix (Invitrogen, Carlsbad, CA). Cycling con-
ditions were as follows: reverse transcription at 51jC for
25 minutes, inactivation of reverse transcriptase and activa-
tion of Platinum Taq DNA polymerase (Invitrogen) at 94jC
for 2 minutes, 35 cycles of 94jC for 15 seconds, 55jC for
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30 seconds, and 68jC for 1 minute, with a final extension at
68jC for 5 minutes. The resulting PCR product (10 ml) was
analyzed on 2% agarose gels stained with ethidium bromide.
Quantitation of bands was performed with the National Insti-
tutes of Health Image J software (version 1.62).
Statistical Analysis
All experiments were performed in triplicate. Results are
expressed as mean ± SD. Statistical significance was deter-
mined by two-tailed Student’s t test and equal variances
using Microsoft Excel (Microsoft, Redmond, WA) and ex-
pressed as P < .05.
Results
Growth-Inhibitory Effect of SNS-032
In this study, we investigated the effects of the cell cycle
inhibitor SNS-032 on several physiologic events, including
migration, capillary formation, and VEGF regulation, that are
critical in tumor growth and metastasis. First, we measured
the growth characteristics of both endothelial and glioma cells
in response to SNS-032 using the CTG assay (Promega).
As shown in Figure 1, A and D, HUVECs and U87MG cells
were treated with increasing concentrations of SNS-032
(0–0.5 mM) from 0 to 72 hours. In this assay, percent cell
growth was calculated relative to 100% growth at the time
of SNS-032 addition. We observed that SNS-032 dose-
dependently inhibited the growth of both cell lines. A four-fold
increase (400%) in the growth of HUVECs was noticed at
72 hours in the absence of SNS-032. Treatment with 0.1 mM
SNS-032 decreased cell growth by almost two-fold (150%
and 200%) at 48 and 72 hours, respectively (Figure 1A).
Complete growth inhibition was obtained at 48 hours when
HUVECs were treated with higher doses of SNS-032 (0.3 and
0.5 mM). We also noticed that the treatment of SNS-032 at
these two concentrations had an even lower cell growth
below 100% at 72 hours, indicating possible cell death. We
then performed TBE assay (Figure 1B) to determine the
viability of HUVECs using identical doses of SNS-032 and,
at the same time, points used in CTG experiments (Fig-
ure 1A). Our results showed significant death of HUVECs
Figure 1. Effect of SNS-032 on HUVEC and U87MG cellular growth and viability. (A and D) Cell growth was measured by CTG luminescent assay in 96-well plates
in the presence of increasing doses of SNS-032, as indicated, for 24, 48, and 72 hours, and the results are expressed as percent growth inhibition in response to
SNS-032 (A, HUVEC; D, U87MG). *P < .001 compared with untreated control (0 M). (B and E) Cell viability was measured by TBE assay. Treatment conditions
were identical as indicated in the CTG assay, and results were expressed as percent viability (B, HUVEC; E, U87MG). *P < .01 compared with untreated control
(0 M). (C and F) Immunoblot analysis of survivin. Cells were treated as indicated, and lysates were collected at the indicated time points and immunoblotted with
survivin antibodies (C, HUVEC; F, U87MG). Bars = SD of six replicates from two independent experiments.
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(> 60%) at 72 hours when treated with 0.5 mM SNS-032. In
the case of U87MG cells, a similar growth-inhibitory effect of
SNS-032 was obtained. An exponential growth curve was
attained in untreated cells where a six-fold growth induction
(600%) was observed after 72 hours of incubation. However,
a two-fold inhibition (300%) of U87MG cell growth was
found at 72 hours in the presence of 0.1 mM SNS-032, and
treatment with higher doses of SNS-032 (0.3 and 0.5 mM)
prevented cell proliferation by almost three-fold (200%; Fig-
ure 1D). In contrast to HUVECs, growth inhibition of U87MG
cells was not associated with cell death, as confirmed in TBE
assay (Figure 1E ). The expression level of survivin, which is
an antiapoptotic protein, was also measured in response to
SNS-032 in both cell lines. A temporal decrease in survivin
expression was noticed in HUVECs (Figure 1C) in response
to SNS-032, whereas no significant change in survivin level
was observed in U87MG cells (Figure 1F ) in the presence
of 0.5 mM SNS-032. We observed no cytotoxic effect of SNS-
032 in these two cell lines for 24 hours; therefore, we selected
a treatment time frame of V 24 hours for SNS-032 for the
remaining experiments.
SNS-032 Inhibited Endothelial Tube Formation
An important function of HUVEC is that it can form capillary-
like structures spontaneously on Matrigel; this function is
crucial in blood vessel formation. Because SNS-032 strongly
inhibits HUVEC cell survival and growth, we examine the ef-
fect of this drug on HUVEC function. In this study, a HUVEC
suspension containing increasing doses of SNS-032 (0.0, 0.1,
0.3, and 0.5 mM) was plated on Matrigel-coated plates. In a
normal growth medium, HUVECs align and form cords that
ultimately become the pattern for new capillary structure
(Figure 2A). In this study, we counted the total number of
branched tubes per field formed after 8 hours of treatment
with SNS-032. The data showed that treatment of SNS-032
resulted in a dose-dependent inhibition of capillary tube for-
mation. Capillary formation was inhibited by 27% at 0.1 mM
and by 65% at 0.3 mM, whereas at 0.5 mM SNS-032, > 90%
of capillary formation was inhibited (Figure 2B). A bar graph
(pooled data from three independent experiments) shows
that SNS-032 significantly reduced the average number of
branched tubes compared to untreated controls, and reduction
was in an SNS-032 dose-dependent fashion.
SNS-032 Inhibited Endothelial Cell Migration
The migration and invasion of endothelial cells through
basement membranes are a crucial step in the develop-
ment of new blood vessels [39,40]. In this experiment, we
measure the ability of SNS-032 in these critical events in
endothelial cells using a migration chamber. HUVECs (2 
104) were seeded onto chamber inserts and allowed to
migrate for 8 hours. Representative images are shown in
Figure 3A, and pooled results from three independent ex-
periments are plotted in Figure 3B. The data demonstrated
that SNS-032 treatment efficiently suppressed HUVEC mi-
gration for 8 hours in a dose-dependent manner. SNS-032
treatment inhibited 36%, 50%, and 60% of endothelial cell
migration at 0.1, 0.3, and 0.5 mM, respectively. We also
monitored HUVEC migration in the presence of SNS-032
at an earlier time point (3 hours) and found similar results
(data not shown).
SNS-032 Inhibited VEGF Expression
VEGF is a critical factor in new blood vessel formation
[4,41,42]. In a tumor microenvironment, cancer cells secrete
a high level of VEGF that binds to receptors on surrounding
Figure 2. Effect of SNS-032 on tube formation by HUVECs. Cells were
seeded on Matrigel-coated wells in the presence of different doses of SNS-
032, as indicated, and incubated for 8 hours to form a capillary network, and
the total number of branched tubes was then counted. The assay was run in
duplicate and repeated thrice. (A) Representative images of capillary network
formation. (B) Statistical analysis of three independent experiments. Bars,
SD. *P < .05 and **P < .001 compared with untreated control.
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endothelial cells, promoting endothelial cell migration, pro-
liferation, and differentiation, as well as tube formation
[43,44]. In this experiment, we measure the effect of SNS-
032 on the VEGF level in these two cell lines (U87MG and
HUVECs) at different concentrations by ELISA. Data pre-
sented in Figure 4A show that the treatment of SNS-032 at
0.3 mM for 24 hours markedly reduced (72%) the secretion of
VEGF by U87MG cells. An almost-complete inhibition was
Figure 3. Effect of SNS-032 on the migration of HUVECs. Cells were seeded
onto PET membrane insert with or without SNS-032, as indicated. The insert
was then placed into the well; after 8 hours, migrated cells were stained and
photographed. The assay was run in duplicate and repeated thrice. (A) Rep-
resentative images of endothelial cell migration were shown. (B) The total
number of migrated cells per field (200) was measured. Bars = SD calcu-
lated from three independent experiments. **P < .001, significantly different
from untreated control.
Figure 4. SNS-032 prevents VEGF expression in both glioblastoma and
endothelial cells. Expression of VEGF in U87MG and HUVECs was deter-
mined by ELISA (A and B), RT-PCR (C), and quantitation of VEGF mRNA
bands (D). Cells were exposed to different doses of SNS-032, as indicated,
for 24 hours. (A) VEGF protein released by U87MG cells into the conditioned
medium was measured by ELISA kit. Bars = SD (n = 3). *P < .05 and **P <
.001 compared with untreated control. (B) HUVECs were treated as indi-
cated. Conditioned media were collected and then concentrated up to 10-fold
using a 10-kDa molecular weight cutoff centricon concentrator (Amicon;
Millipore, Billerica, MA). VEGF protein was measured by ELISA kit. Bars =
SD (n = 3). **P < .001 compared with CoCl2 treatment. (C) Effect of SNS-032
on VEGF mRNA in U87MG cells. The expression of VEGF mRNA was
analyzed by RT-PCR. -Actin expression was included as an internal control.
(D) VEGF mRNA expression in U87MG cells was quantitated by densi-
tometry and then normalized with -actin, as shown in the bar graph. The
ratios of VEGF/-actin at 0 M SNS-032 were assigned to be 100%. Bars =
SD (n = 3). **P < .001 compared with untreated control.
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observed at 0.5 mM SNS-032 at the same time point,
whereas a 21% inhibition of VEGF level was obtained at
0.1 mM SNS-032. Pooled results from three independent
experiments are shown in Figure 4A. We also demon-
strated that this inhibition of VEGF by SNS-032 in U87MG
cells was not due to cell death, as shown in Figure 1. In
contrast, untreated HUVECs released a very low level VEGF
(0.75 pg/ml), as shown in Figure 4B; therefore, we use CoCl2
to induce VEGF expression in this cell line. CoCl2 is a
hypoxia mimetic agent and is known to induce VEGF ex-
pression by upregulating hypoxia-inducible factor (HIF) 1
[25]. A 2.5-fold induction of VEGF was achieved on treat-
ment with CoCl2, and a dose-dependent decrease of VEGF
was noticed when increasing concentrations of SNS-032
were added in the presence of CoCl2 (Figure 4B). To inves-
tigate whether SNS-032 inhibited VEGF secretion through
its ability to inhibit gene transcription, we next determined
the effect of SNS-032 treatment on the levels of VEGF
mRNA expression in U87MG cells. Thus, after collecting
conditioned medium for VEGF estimation, total RNA was
extracted from remaining cells, and mRNA levels of VEGF
were measured by RT-PCR (Figure 4C). VEGF exists in at
least four different isoforms of 121, 165, 189, and 206 amino
acids that are produced by the alternative splicing of VEGF
mRNA from a single gene [45,46]. In the majority of cells and
tissues, isoforms of VEGF121 and VEGF165 are detected.
Our results show that treatment with SNS-032 reduces
the level of these two isoforms in U87MG cells in a dose-
dependent fashion (Figure 4C). Data presented in Figure 4D
are a densitometric analysis of the relative expression level of
these two isoforms that were performed in three independent
experiments. Around 85% and 60% reduction in VEGF121 and
VEGF165 isoforms, respectively, were obtained in response to
0.3 mM SNS-032 in U87MG cells (P < .001).
SNS-032 Inhibited U87MG Cell– Induced Capillary
Formation of Endothelial Cells
In this experiment, our objective was to determine: 1)
whether glioblastoma cells can induce the capillary formation
of HUVECs; and 2) to monitor the effect of SNS-032 on this
event. Therefore, we used conditioned media from U87MG
cells treated with or without SNS-032, as described in
Materials and Methods section. A HUVEC suspension was
then prepared in this conditioned medium and plated onto a
Matrigel-coated plate. Images were taken after 8 hours of
incubation; results are presented in Figure 5A, and pooled
results from three independent experiments are shown in
Figure 5B. It is clearly seen from the results that the condi-
tioned medium (without SNS-032) from U87MG cells in-
duced tube formation by three-fold compared to controls
(nonconditioned media, DMEM only). However, SNS-032–
treated conditioned media from U87MG cells produced a
complete prevention of tube formation (Figure 5B; P < .001).
We also measured the VEGF level in the conditioned
medium obtained from U87MG cells, and a 50% inhibition
of VEGF production was noticed in the presence of SNS-032
(Figure 5C). These results demonstrate that the function of
HUVEC is augmented by glioblastoma cells as measured by
capillary formation and that this activity is downregulated
when treated with SNS-032. Blocking VEGF synthesis in
glioblastoma cells is one of the major factors causing the
inhibition of HUVEC function.
SNS-032 Inhibited U87MG Cell– Induced Migration
of Endothelial Cells
Using a coculture assay, we next tested the effect of SNS-
032 on endothelial cell (HUVEC) migration induced by tumor
cells. As mentioned earlier, the coculture study was per-
formed based on the previous assay performed by Tsujii
et al., and a schematic diagram of this assay is presented in
Figure 6A. Representative images are shown in the middle
panel (Figure 6, B–D), and pooled results from three inde-
pendent experiments performed in triplicate are shown as
a bar graph in the lower panel (Figure 6E ). As shown in
Figure 6E, HUVECs cocultured with U87MG cells migrated
2.6-fold faster compared to HUVECs alone (Figure 6B). This
increased migration of HUVECs was prevented significantly
when U87MG cells were treated with SNS-032. In a parallel
experiment, we collected the medium from the bottom
chamber and measured the VEGF level, finding it to be sig-
nificantly inhibited in the presence of SNS-032 (data not
shown). These results show an increased migration of endo-
thelial cells through a matrix when cocultured with glio-
blastoma cells, and this migration is severely inhibited
when U87MG cells are treated with SNS-032.
SNS-032 Partially Inhibited VEGF-Induced Capillary
Formation and Migration of Endothelial Cells
In the previous experiment, we demonstrated that SNS-
032 inhibited tumor cell– induced capillary formation and the
motility of endothelial cells using a coculture assay. The
purpose of this experiment is to investigate the effect of
SNS-032 on endothelial cell capillary formation and migra-
tion when a functionally active VEGF was added to the
culture medium. An active form of human recombinant VEGF
(100 ng/ml) was added to the growth factor–reduced endo-
thelial cell medium either in the presence or in the absence of
SNS-032, and then we measured capillary formation and
migration. Results presented in Figure 7, A and B, show that
exogenous treatment of VEGF induced tube formation by
almost three-fold when compared to untreated controls.
However, the induction was partially inhibited (f23%), as
opposed to near-complete inhibition observed in Figure 5B
by SNS-032 treatment. In the next experiment, we deter-
mined the effect of SNS-032 on HUVEC migration induced
by the addition of exogenous VEGF. Results indicate a two-
fold induction of endothelial cell migration at 8 hours after the
addition of VEGF, and partial reduction in migration (< 25%)
was observed in the presence of SNS-032 (Figure 7, C and
D). These results indicate that SNS-032 prevents in vitro
angiogenesis primarily by blocking the production of VEGF.
Discussion
Angiogenesis, or the formation of new blood vessels, is
important for tumor growth and progression, as the process
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oxygenates and feeds the proliferation of tumor cells while
quickly ridding cells of CO2 and waste metabolites. It has
been widely reported that tumor cells produce numerous
angiogenic factors, including VEGF, FGF, epidermal growth
factor (EGF), PDGF, and matrix metalloproteinase en-
zymes. These factors play a pivotal role in the development
of tumor angiogenesis by stimulating endothelial cell pro-
liferation, migration, and capillary tube formation [4,47,48].
However, among all angiogenic factors, VEGF is identified
as a key mediator of angiogenesis [4,42]. Glioblastomas are
one of the most highly vascularized and angiogenic solid
tumors known, where aggressive blood vessel formation
and glioma cell invasion result in the failure of regular con-
ventional therapies such as surgery, radiation, and chemo-
therapy [12]. These tumors secrete a very large quantity
of VEGF protein into the surrounding microenvironment,
thereby allowing endothelial cell proliferation, migration,
and tube formation [40,49,50].
Figure 5. SNS-032 inhibited the U87MG cell – induced tube formation of HUVECs. U87MG cells were treated with or without SNS-032 for 8 hours and then
incubated with fresh media without SNS-032 for 24 hours, followed by the collection of conditioned media (CM). (A) Capillary network formation of HUVECs using
CM. No-treatment panel indicates that a blank medium (serum-free DMEM) was added to HUVECs for network formation. In the other two panels, CM was added
to HUVECs, as indicated. The tube formation assay of HUVECs was performed using CM prepared from U87MG cells instead of HUVEC medium. (B) The total
number of branched tubes was counted, and results from three independent experiments were presented for statistical analysis. Error bars = SD. **P < .001
between untreated CM and SNS-032– treated CM or blank CM. (C) VEGF level was analyzed in the conditioned medium by ELISA.
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In the present study, we show that SNS-032 blocked the
proliferation, capillary formation, and migration of endothelial
cells, all of which are critical steps for angiogenesis. Flavo-
piridol, a similar class of inhibitor, showed antiproliferative
activities by blocking cells at either G1/S or G2/M phases
of the cell cycle and is associated with the downregulation
of cyclins and other biologic CDK inhibitors [51,52]. Tran
et al. [53] and Wall et al. [54] showed that induction of
apoptosis in endothelial cells by cell cycle inhibitors may
be due to the downregulation of survivin, which is an anti-
apoptotic protein overexpressed in endothelial cells and is
associated with resistance to apoptosis. We also observed a
time-dependent decrease of survivin expression in HUVECs
by SNS-032.
We found that the basal VEGF level in U87MG cells is
significantly high and that SNS-032 dose-dependently down-
regulates both mRNA and protein levels of VEGF (Figure 4,
A and C). The basal level of VEGF in HUVEC was very low,
but in the presence of CoCl2, an increase in VEGF release in
the media was noticed, and this induction was inhibited by
SNS-032 (Figure 4B). Melillo et al. [24] have previously
shown that flavopiridol prevents VEGF in human monocytes
under hypoxic conditions. In U87MG cells, induction of
VEGF was also prevented by flavopiridol, possibly through
the downregulation of HIF-1a [25]. In our study, we also
observed the downregulation of CoCl2-induced HIF-1a in
HUVECs by SNS-032 (data not shown). In this study, using a
coculture assay, we examined the effect of this inhibitor on
glioblastoma cell– induced migration and on the tube forma-
tion of endothelial cells. Treatment with SNS-032 decreased
VEGF secretion by U87MG cells and thereby reduced endo-
thelial cell migration and tube formation.
Overexpression of VEGF and VEGF receptors correlates
with increased microvessel density, proliferation, and tumor
growth rate, which lead to poor patient prognosis in a variety
of malignancies [1,55]. In this study, we analyzed cellular
Figure 6. Effect of SNS-032 on the migration of HUVECs cocultured with U87MG cells. U87MG cells were cultured in the well (lower chamber). Cells were then
treated with or without SNS-032 for 8 hours. After treatment, the medium from the lower chamber was replaced with fresh DMEM without SNS-032, and the insert
(upper chamber) containing a monolayer of HUVECs in DMEM was then placed into the well. After 8 hours, migrated cells were photographed and counted.
(A) Schematic diagram of coculture assay. (B) Control. HUVECs were seeded onto the upper chamber, whereas the bottom chamber contains only DMEM without
U87MG cells. (C) HUVECs cocultured with U87MG cells untreated with SNS-032. (D) HUVECs cocultured with U87MG cells pretreated with 0.5 M SNS-032.
(E) Pooled data from three experiments for statistical analysis comparing the number of migrated cells in coculture with and without SNS-032 treatment. Bars = SD.
**P < .001 between treated and untreated U87MG cells with SNS-032 or blank culture medium.
378 SNS-032 Inhibits In Vitro Angiogenesis Ali et al.
Neoplasia . Vol. 9, No. 5, 2007
proliferation by measuring the growth of HUVECs and
U87MG cells in the presence of SNS-032 at increasing
concentrations. In both cell lines, it was noticed that SNS-
032 prevented growth at all concentrations up to 48 hours
(Figure 1, A and D). In general, antiangiogenic inhibitors
exhibit cytotoxicity and induce the apoptosis of endothelial
cells. When cells were continuously exposed to SNS-032
for longer periods of time (up to 72 hours), significant endo-
thelial cell death was noticed. However, almost no cell
death was observed in U87MG cells even after 72 hours of
exposure of SNS-032; instead, these cells experienced
complete growth arrest (Figure 1, D and E ). Because the
experiments were performed within 24 hours of exposure of
SNS-032, reduction in VEGF, migration, and capillary net-
work formation occurred mostly in the absence of significant
cell death.
Multiple factors are involved in the upregulation of VEGF
synthesis. Tsujii et al. [56] demonstrated that the over-
expression of COX-2 in Caco2 cells induced VEGF levels.
Furthermore, using a coculture assay, Tsujii et al. reported
that a COX-2–specific inhibitor (NS-398) blocked PGE2
synthesis in colon carcinoma cells, thus affecting tube for-
mation and the migration of endothelial cells. As mentioned
earlier, we showed that SNS-032 inhibits IL-1b– induced
COX-2 expression and PGE2 synthesis in lung tumor cells
[27]. But the precise mechanism of COX-2–dependent
VEGF regulation is still not clear. We demonstrated that
SNS-032 mostly inhibits the transcription of VEGF. However,
we noticed that SNS-032 was also effective in preventing
either capillary formation or migration when an active re-
combinant VEGF was added exogenously into the growth
factor–reduced endothelial cell medium. Currently, we are
elucidating the molecular pathways of this event in response
to SNS-032. In conclusion, our data suggest that SNS-032
downregulates these critical steps for tumor-induced angio-
genesis and that this action is partially attributable by the
blocking of VEGF.
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